Beximco Pharmaceuticals Ltd.

A focus on active pharmaceutical ingredients, data integrity and sterility assurance was evident in inspection reports, an untitled letter and a warning letter that the US Food and Drug Administration

Bangladeshi generics giant Beximco Pharmaceuticals Ltd. continued its quarterly trend of declining profits, despite net revenue growth, as macroeconomic factors dragged down its bottom line. The fir

A substantial decline in vaccine income, a drop in gross margin and a slight increase in effective tax rate all contributed to a 28% consolidated earnings decline at Beximco Pharmaceuticals Ltd. dur

Off-patent drug sector stakeholders have expressed concerns about the impact of rising inflation on the generic and biosimilar industries going forward into 2023, with some calling for interventions f